Last 17 quarters of trend data · Healthcare · Neuroscience Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q1 '22 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.53 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.30 | 4.87 | 4.80 | 3.44 | 3.47 | 36.07 | 12.60 | 8.00 | 5.48 | 4.24 | 6.87 | 3.55 | 8.47 | — | — | — | — | — |
| — | -86.5% | -61.9% | -57.0% | -36.7% | +750.0% | +83.5% | +125.6% | -35.3% | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q1 '22 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q1 '22 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -165.9% | -13.8% | -11.7% | -66.7% | -28.0% | -165.0% | -102.1% | -83.1% | -70.6% | -62.9% | -45.6% | -92.7% | -77.1% | -105.8% | — | -152.1% | -62.2% | — |
| — | +91.6% | +88.6% | +19.8% | +60.3% | -162.2% | -123.8% | +10.3% | +8.4% | +40.5% | — | +39.1% | -23.8% | — | — | — | — | — | |
| ROA | -149.0% | -13.7% | -11.2% | -63.9% | -26.8% | -135.6% | -82.5% | -66.8% | -56.1% | -49.6% | -39.3% | -83.0% | -55.9% | -60.0% | -213.6% | -69.2% | -48.5% | — |
| — | +89.9% | +86.4% | +4.3% | +52.3% | -173.5% | -110.0% | +19.5% | -0.5% | +17.3% | +81.6% | -19.9% | -15.2% | — | — | — | — | — | |
| ROIC | -461.4% | -19.1% | -19.3% | -97.6% | -41.6% | — | — | — | — | — | — | -215.0% | -86.9% | -87.1% | — | -905.2% | — | — |
| — | — | — | — | — | — | — | — | — | — | — | +76.3% | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q1 '22 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.01 | 1.61 | — | — | 0.18 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | -92.6% | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 15.75 | 200.08 | 82.16 | 15.75 | 90.53 | 2.79 | 12.86 | 3.99 | 6.11 | 3.68 | 5.70 | 8.70 | 6.99 | 0.16 | 0.12 | 0.36 | 4.16 | — |
| — | +7069.6% | +539.1% | +294.6% | +1382.4% | -24.2% | +125.7% | -54.1% | -12.6% | +2154.8% | +4707.3% | +2312.2% | +68.0% | — | — | — | — | — | |
| Quick Ratio | 15.75 | 200.08 | 82.16 | 15.75 | 90.53 | 2.79 | 12.86 | 3.99 | 6.11 | 3.68 | 5.70 | 8.70 | 6.99 | 0.16 | 0.12 | 0.36 | 4.16 | — |
| — | +7069.6% | +539.1% | +294.6% | +1382.4% | -24.2% | +125.7% | -54.1% | -12.6% | +2154.8% | +4707.3% | +2312.2% | +68.0% | — | — | — | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | -1.12 | -7.39 | -3.28 | -810.28 | -763.14 | -380.94 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 17 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MIRA stock.
MIRA Pharmaceuticals, Inc.'s current P/E is -2.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking MIRA Pharmaceuticals, Inc.'s business trajectory between earnings reports.